EyePoint (EYPT) Gross Margin (2018 - 2026)

EyePoint (EYPT) posted Gross Margin of 24.14% for Q1 2026, down 38.92% sequentially from 39.52% in Q4 2025, and down 7257.0% YoY from 0.34% in Q1 2025.

EyePoint (EYPT) Gross Margin (2018 - 2026) Analysis & Trends

EyePoint has reported Gross Margin for 9 years, with the latest figure at 24.14% in Q1 2026.

  • Quarterly Gross Margin fell 7257.0% year-over-year to 24.14% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.51% (down 1679.0% YoY) and the FY2025 annual result came in at 93.41%, up 199.0% from the prior year.
  • Gross Margin declined to 24.14% in Q1 2026 per EYPT's latest filing, from 39.52% in the prior quarter.
  • Over five years, Gross Margin peaked at 96.91% in Q2 2025 and troughed at 24.14% in Q1 2026.
  • A 5-year average of 77.87% and a median of 85.97% in 2022 frame the typical range for Gross Margin.
  • The sharpest annual moves came in 2023 and 2026: Gross Margin soared 2526 bps in 2023, then tumbled 7257 bps in 2026.
  • Over 5 years, Gross Margin stood at 67.63% in 2022, then jumped by 37 bps to 92.89% in 2023, then climbed by 0 bps to 92.96% in 2024, then sank by 57 bps to 39.52% in 2025, then tumbled by 39 bps to 24.14% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods registered 24.14%, 39.52%, and 25.36% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 85.33%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 91.59%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 90.68%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 89.76%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 60,631,834.75%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 76.90%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 84.20%
10 EyePoint 1.25 Bn 1.07 Bn 507,000.00 100.00%

Historic Data

Download Data
DateValue
Jun 30, 2026 100.00%
Mar 31, 2026 24.14%
Dec 31, 2025 39.52%
Sep 30, 2025 25.36%
Jun 30, 2025 96.91%
Mar 31, 2025 96.71%
Dec 31, 2024 92.96%
Sep 30, 2024 93.01%
Jun 30, 2024 85.22%
Mar 31, 2024 93.50%
Dec 31, 2023 92.89%
Sep 30, 2023 92.09%
Jun 30, 2023 80.32%
Mar 31, 2023 91.67%
Dec 31, 2022 67.63%
Sep 30, 2022 85.97%
Jun 30, 2022 85.01%
Mar 31, 2022 80.88%
Dec 31, 2021 73.73%
Sep 30, 2021 79.85%